How to Integrate Novel Treatment Classes for R/R Myeloma Into Clinical Practice: Information on Selinexor, Venetoclax, and Melphalan Flufenamide

In this podcast episode, Tiffany Richards, PhD, ANP-BC, AOCNP, highlights practical considerations for integrating novel treatments— selinexor, venetoclax, and melphalan flufenamide—into clinical practice for patients with multiple myeloma after multiple relapses. Check back to hear part 2 of this series with a discussion on BCMA-targeted therapy by Donna Catamero, ANP-BC, OCN, CCRC, Associate Director of Myeloma Translational Research at the Mount Sinai Health System.Presenter:  Tiffany Richards, PhD, ANP-BC, AOCNPNurse PractitionerDepartment of Lymphoma/MyelomaThe University of Texas MD Anderson Cancer CenterHouston, TexasCE/AAPA credit available by visiting the online program: https://bit.ly/3ee9IvsLink to full program, including downloadable slidesets: https://bit.ly/3ee9Ivs 

There are no comments yet.

Please log in to write the first comment.